Experimental cocktail targets Hard-to-Treat myeloma
NCT ID NCT01562405
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called sotatercept (ACE-011) combined with standard myeloma drugs lenalidomide or pomalidomide and dexamethasone in 33 patients whose multiple myeloma has returned or stopped responding to treatment. The main goal is to find the safest dose of sotatercept and begin to see if the combination can shrink tumors or slow the disease.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sotatercept (ACE-011) combined with lenalidomide or pomalidomide and dexamethasone
What this could lead to
If this works, it could point toward a new treatment option for multiple myeloma that has stopped responding to other therapies.
What could go wrong
This is a very early, small Phase 1 trial focused on safety and dosing, not yet testing effectiveness. The combination may cause side effects or fail to control the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Emory University
Atlanta, Georgia, 30322, United States
-
Massachusetts General Hosptial
Boston, Massachusetts, 02115, United States